These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 641385

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
    Dempfle CE, Argiriou S, Kucher K, Müller-Peltzer H, Rübsamen K, Heene DL.
    Blood; 2000 Oct 15; 96(8):2793-802. PubMed ID: 11023513
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P, Kant KS, Dosekun A, Frazier J, Allen C, Pollak VE.
    J Lab Clin Med; 1985 Jan 15; 105(1):99-107. PubMed ID: 3871465
    [Abstract] [Full Text] [Related]

  • 6. The antiplatelet activity of ancrod on administration to rabbits.
    Chang MC, Huang TF.
    J Lab Clin Med; 1995 Apr 15; 125(4):508-16. PubMed ID: 7706907
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S, Wadhwa NK, Kant KS, Pollak VE, Glas-Greenwalt P, Weiss MA, Hong CG.
    Q J Med; 1988 Nov 15; 69(259):879-905. PubMed ID: 3078212
    [Abstract] [Full Text] [Related]

  • 10. Defibrinogenating enzymes.
    Bell WR.
    Drugs; 1997 Nov 15; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [Abstract] [Full Text] [Related]

  • 11. The clotting of a snake (Crotalus viridis Helleri) plasma and its interaction with various snake venoms.
    Denson KW.
    Thromb Haemost; 1976 Apr 30; 35(2):314-23. PubMed ID: 989631
    [Abstract] [Full Text] [Related]

  • 12. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T, von Lessen A, Welters I, Wagner RM, Ruwoldt R, Boldt J, Hempelmann G.
    Infusionsther Transfusionsmed; 1994 Aug 30; 21(4):244-50. PubMed ID: 7950289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury.
    Simpson PJ, Schelm JA, Smith GF.
    J Pharmacol Exp Ther; 1991 Feb 30; 256(2):780-6. PubMed ID: 1704437
    [Abstract] [Full Text] [Related]

  • 16. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
    Matsuda M, Saeki E, Kasamatsu A, Nakamikawa C, Manabe S, Samejima Y.
    Thromb Res; 1985 Feb 01; 37(3):379-90. PubMed ID: 3992527
    [Abstract] [Full Text] [Related]

  • 17. Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
    Dempfle CE, Alesci S, Kucher K, Müller-Peltzer H, Rübsamen K, Borggrefe M.
    Thromb Res; 2001 Dec 15; 104(6):433-8. PubMed ID: 11755954
    [Abstract] [Full Text] [Related]

  • 18. Review of some unusual effects of calcium binding to fibrinogen.
    Mihalyi E.
    Biophys Chem; 2004 Dec 20; 112(2-3):131-40. PubMed ID: 15572240
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.